## Pharmacovigilance and postregistration studies capacity

Haggar Hilda Ampadu (Deputy Director)

&

Alex Dodoo (Director)

WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, Accra Ghana

EDCTP Stakeholder Meeting on Capacity Development Berlin, Germany, 3<sup>rd</sup> July 2014



### Overview

Capacity for PV and post-registration studies

Current initiatives

 Building upon existing activities and structure

Way forward and conclusions



## Capacity for Pharmacovigilance

WHO definition for pharmacovigilance:
The science and activities relating to
the detection, assessment,
understanding and prevention of
adverse effects or any other
possible drug-related problems

The importance of pharmacovigilance, WHO, 2002

**Drug** = medicines, vaccines, herbals etc.

"Drug-related problems" include SSFFCs (spurious, sub-standard, fake, falsified and counterfeit medicines), rumour-induced problems, problems during mass treatment programmes



## Capacity for PV

- No objective measure currently exists for measuring capacity for PV in member states
- WHO PV Indicator has been recently launched but it is yet to be fully validated
- Indicator-based Pharmacovigilance Assessment Tool (IPAT) from MSH/SIAPS has also been developed but not yet validated
- WHO's concept of "minimal capacity is thus mostly used"
- Or the number of ADR reports (Individual Case Safety Reports ICSRs) submitted annually by the country to the WHO ICSR database Vigibase –per million inhabitants

WHO COLLABORATING CENTRE FOR ADVOCACY

## Minimal Capacity

- According to WHO, a country is considered to have "minimal capacity" for PV if it has the following:
  - A National PV Centre with at least one full-time dedicated staff and in membership of the WHO Programme for International Drug Monitoring
  - 2. A national spontaneous reporting system
  - 3. A database for adverse drug reactions
  - 4. A Pharmacovigilance Advisory Committee
  - 5. A Communication Strategy



### The African Situation

- Regardless of what measure is used, PV and post-registration studies (PRS) capacity in Africa is weak
- The situation is improving thanks to dedicated and continuous efforts by WHO and the WHO-CC in Accra, Morocco together with other partners
- But support is needed to ensure sustainability of the gains made so far



## The WHO PV Programme


(as at 30<sup>th</sup> June 2014)





# The status of Africa within the WHO PV Programme

(as at 30<sup>th</sup> June 2014)



Ass.

#### **Members**

- 1. Algeria
- 2. Burundi
- 3. Gambia
- 4. Guinea-Bissau
- 5. Zanzibar



CENTRE FOR TROPICAL CLINICAL
PHARMACOLOGY & THERAPEUTIC

WHO COLLABORATING CENTRE FOR ADVOCA

### However....

- Most of the countries only joined the WHO Programme recently
  - 2009-2014: 17 members out of 32
  - 2000-2009: 10 members
  - 1992 (South Africa; Morocco) 1999: 5
- Number of ICSRs submitted very very low
  - Less than 1% of the 9million ICSRs in Vigibase come from Africa
- WHO-CC in collaboration with WHO and UMC have been investigating and supporting......



## Reporting In Africa

#### Total number of ICSRs from African countries (cumulative)

African countries			
2004	6,424		
2005	7,246		
2006	8,401		
2007	10,786		
2008	11,319		
2009	16,638		
2010	20,895		
2011	26,650		
2012	41,133		
2012.5	49,387		
2013	55,192		
	62,967		
2013.5	67,710		
2013.667	,		

African members	of the WHO	Programme
-----------------	------------	-----------

2004	8
2005	9
2007	11
2008	15
2009	18
2010	24
2011	26
2012	29
2013	31



WHO Collaborating Centre for Advocacy and Training in PV, Accra, Ghana and Capacity Development for PV in Africa



## WHO-CC Terms of Reference - I

- The terms of reference of the WHO-CC
  - Training in pharmacovigilance in African countries for building and strengthening of spontaneous adverse drug reaction reporting systems
  - Advocacy for pharmacovigilance across Africa either alone or in collaboration with WHO
  - Promoting the integration of pharmacovigilance into public health programmes
  - Technical support to national pharmacovigilance centres



### Terms of Reference - II

- Support in communication and crisis management to national pharmacovigilance centres
- Acquisition (from WHO, UMC) and distribution of needed literature and technical tools to national pharmacovigilance centres and governments
- Research in pharmacovigilance including cohort event monitoring of specified medicines
- Assistance in the development and maintenance of pregnancy registers

## RCORE designation – May 2014



Ref: RCORE/01/2014 Date: 02 May 2014

Prof Alex Dodoo
Director, Centre for Tropical Clinical Pharmacology & Therapeutics
Director, WHO Collab. Centre for Advocacy and Training in Pharmacovigilance
University of Ghana Medical School
P. O. Box 4236, Accra, Ghana: Tel/Fax: +233-302-668219

Dear Prof. Dodoo,

Re: Application for designation as a Regional Centre of Regulatory Excellence

Following review of your application, I am happy to inform you that your institution has been approved for designation as a Regional Centre of Regulatory Excellence (RCORE) in Pharmacovigilance.



## 2013/2014 Activities-I

### **Country Visits**

The following countries were visited for strengthening in PV and Regulatory Activities

- **2013** 
  - Eritrea, Liberia; Rwanda; Kenya, Guinea; Uganda,
     Angola; South Africa, Togo
- **2014** 
  - Mauritius, Namibia, Mauritania, Burundi, Tanzania and counting....
  - Scheduled: Zanzibar(Jul26-Aug 1), Djibouti
     (September)



WHO COLLABORATING CENTRE FOR ADVOC & TRAINING IN PHARMACOVIGILANCE

### Our Flagship 4 week Pharmacovigilance Fellowship Course

#### **Pharmacovigilance Fellowship**

- 4-week training in the theory and practice in PV
- ■Includes hands-on sessions on tools used in PV
- •Field trips to the Ghana National PV centre, hospitals, research institutions and rural field stations


#### 4 courses so far:

17<sup>th</sup> June – 12<sup>th</sup> July, 2013 16<sup>th</sup> September – 11<sup>th</sup> October, 2013 2<sup>nd</sup> June – 28<sup>th</sup> June 2014 14 July- 8<sup>th</sup> August 2014

### 31 participants from 24 African countries

#### Modules include but not limited to;

- ■Developing an ADR reporting culture
- ■PV methods
- ■Regulatory aspects of PV
- ■Mechanism of ADRs
- Causality Assessment
- ■Research in PV
- Statistics and bioinformatics
- Data management



#### Aims:

The Fellowship is aimed at providing the following:

- The theory and practice of Pharmacovigilance (PV).
- · Practical hands-on training in PV.
- Training on the use of PV associated softwares.
- Field visits to introduce participants to the real life practice of PV in hospitals, regulatory and industrial settings.

#### **Duration & Dates:**

Four (4) weeks

First offering: 2nd - 27th June, 2014 Application Deadline: 20th May, 2014 Second offering: 15th September - 10th October, 2014

Application Deadline: 1st September, 2014

#### Registration:

Participation will cost USD 3,300.00 and includes course materials, lunch and two coffee breaks, field trips and visit to tourist sites in and around the capital.

Sponsorship may be available for those who qualify.

The WHO Collaborating Centre

### Pharmacovigilance Fellowship

Application forms & detailed training brochure can be downloaded via the following links:

http://www.who-pvafrica.org http://www.who-umcafrica.org



Centre for Tropical Clinical Pharmacology & Therapeutics UNIVERSITY OF GHANA MEDICAL SCHOOL



WHO Collaborating Centre for Advocacy & Training in Pharmacovigilance Contact: training@who-pvafrica.org or call +233 289 014 000

#### Deliverables:

Certificates of competence will be issued to each participant who successfully completes the program.



This fellowship is being organised in collaboration with Santé-Afrique International Ltd, the leading African organization providing solutions in patient safety, drug safety, vaccine safety, IT solutions for longitudinal data management, electronic data capture systems and patient management systems.

> Visiting Address: 18 Mango Tree Avenue, Asylum Down, Accra, Ghana Mailing Address: P. D. Box LT 282 Larteblokorshie, Accra, Ghana

ICAL UTICS SCHOOL DVOCACY

### **Our Yearly Data Management Course**

WHO Collaborating Centre for Advocacy & Training In Pharmacovigilance Accra, Ghana

#### Data Management for Regulatory Affairs and Public Health

#### Aims:

To equip healthcare professionals with skills and tools needed to effectively manage data in their field of work.

#### Duration & Dates:

Five (5) days; 24th - 28th March, 2014

Cost: \$1950

### Application forms & Detailed Training brochure can be downloaded via the following link: http://www.who-pvafrica.org http://www.who-umcafrica.org

Contact: training@who-pvafrica.org or call +233 289 014 000

#### Modules:

- Design and Development of Data Collection Instruments
- Data Validation Specification (Error/Edit Checks)
- Data Entry Processes
- Data Management Plan (DMP)
- Patient Reported Outcomes
- Introduction to Statistics and Data Management in Public Health
- Local National and International ICSR Databases
- Database Support
- Database Transmission
- Collection of Longitudinal Safety Data -MEDSPINA



Centre for Tropical Clinical Pharmacology & Therapeutics UNIVERSITY OF GHAMA MEDICAL SCHOOL



WHO Collaborating Centre for Advocacy & Training in Pharmacovigilance



In collaboration with Santé-Afrique International Ltd, the leading African organization providing solutions in patient safety, drug safety, vaccine safety, IT solutions for longitudinal data management, electronic data capture systems and patient management systems.

Visiting Address: 18 Mango Tree Avenue, Asylum Down, Accra, Ghana Mailing Address: P. O. Box LT 282 Lartebiokorshie, Accra, Ghana Tel: +233 (0)289 014 000 Email: training@who-pvafrica.org



PHARMACOLOGY & THERAPEUTICS, UNIVERSITY OF GHANA MEDICAL SCHOOL

WHO COLLABORATING CENTRE FOR ADVOCACY & TRAINING IN PHARMACOVIGILANCE

## 2013 Activities-II

- Communication and Crisis Management
  - Providing support to countries in effective
     Communication & Crisis Management
  - Support to Ghana (Ministry of Health) in developing a manual for Communication and Crisis Management for Public Health Programs in collaboration with the WHO Ghana Country Office



### 2013 Activities-III

### **Support in Risk Management Plans**

 Support to the National Drug Authority (Uganda) in the development of an enterprise risk management plan.

- Assistance in providing framework for developing risk management plans
- Support in providing tools for data collection for a risk register



### 2013 Activities - IV

### **Toolkits**

- Pharmacovigilance toolkit (<u>www.pvtoolkit.org</u>)
- Vaccine Pharmacovigilance Toolkit (under development – <u>www.vaccinepvtoolkit.org</u>)
- Malaria Pharmacovigilance Toolkit ( http://pvtoolkit.org/malaria-pv-toolkit/)
  - under revision with new sections and areas



### **EHR for Patient Care and PV (V)**

- MedSpina
  - ■EHR incorporating PV features
  - ■HL-7 framework
  - Longitudinal data collection
- Developed and being deployed in Ghana (now) and Uganda (later this year)





### Meetings-ASoP Dec 3-5 2014, Host-WHO-CC, Accra (VI)


- ASoP is the African Society of Pharmacovigilance
- ■Formed in 2010 and accepted as a Chapter of the International Society of Pharmacovigilance (ISoP) in 2010
- ■A key activity is to bring ALL stakeholders in PV in Africa once a year – to meet, network, share ideas and improve PV in Africa





### Number of People Trained at WHO-CC, Accra since

2013....80!!!!



PHARMACOLOGY & THERAPEUTICS
UNIVERSITY OF GHANA MEDICAL SCHOOL

WHO COLLABORATING CENTRE FOR ADVOCA


## Way Forward - I

- Pharmacovigilance in Africa has improved tremendously over the past 5 years in terms of NUMBERS
  - However, nearly a third of African countries still have no pharmacovigilance capacity at all
- Where PV and PRS capacity exists, the QUALITY is variable; usually very weak
- The focus now is improving <u>quality</u> and not just <u>quantity</u>



## Way Forward - II

- Countries with PV activities do not want to be just data collectors
  - They now want support and training to ANALYSE their data and MAKE DECISIONS based on their data
  - Data analysis; data management skills now deemed essential
  - This calls for broader thinking into DATA CAPTURING approaches – from paper to electronic across the entire spectrum



## Way Forward - III

- There is therefore the need for
  - Training of data management
  - Development of African-specific tools for data capture
    - Electronic health records should now be seriously considered for appropriate sites in Africa
  - Pharmaco-epidemiological studies need to be conceived and undertaken
  - The harmonisation efforts across the continent should consider PV as an essential component of regulatory capacity building

## Way Forward - IV

- The WHO-CC in collaboration with WHO (HQ; AFRO) and partners (AMRH; AU/NEPAD; WAHO; INDEPTH; INESS) have led development of PV across Africa
- There is the need for DEDICATED support for the WHO-CC to continue this important work
- Building parallel structures etc. will not inure to the benefit of anyone
- WHO-CC is ALREADY providing the leadership and advocacy and welcomes ALL partners including the EDCTP.....



# Thank you!!!

